Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best high short interest stocks with highest upside potential. On May 27, Apogee Therapeutics secured $1.3 billion in non-dilutive financing from Blackstone Life Sciences to fund Phase 3 development and commercialization of zumilokibart. The deal includes $800 million in synthetic royalties and $500 million in senior debt, which, alongside existing cash, allows Apogee to reach profitability without further equity raises.
The funding is milestone-based, tied to Phase 3 progress and FDA approval. Blackstone’s commitment (the largest royalty financing for a pre-Phase 3 program) underscores its confidence in zumilokibart’s potential as a first-line treatment for atopic dermatitis and other inflammatory conditions.
Management noted that this partnership provides the capital flexibility needed to advance zumilokibart as a multi-indication therapy. By securing this financial foundation, Apogee Therapeutics Inc. aims to accelerate its pipeline and successfully transition from clinical innovation to commercial launch.
Apogee Therapeutics Inc. operates as a biotechnology company, offering treatment of atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.